Monoclonal antibody capable of analysing subpopulations of hematopoietic and lymphoid cells, and the degree of T cell differentiation. It can be used to identify the effect of CD45 in immune function.
| Inventor | Institute |
|---|---|
| Peter Beverley | Cancer Research UK, London Research Institute: Lincoln's Inn Fields |
| Cat. #: | 151108 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Cell biology;Cell signaling and signal transduction;Immunology;Neurobiology;Stem cell biology;Tissue-specific biology |
| Application: | FACS ; IHC ; IF |
| Target: | Protein tyrosine phosphatase, receptor type, C (PTPRC, CD45) |
| Reactivity: | Human |
| Clone: | HLe-1(2D1) |
| Host: | Mouse |
| Class: | Monoclonal |
| Primary citation: | Bradstock et al. 1980. J Natl Cancer Inst. 65(1):33-42. PMID: 6993744. |
| Alternate name: | Anti-PTPRC |
|---|---|
| Product description: | Monoclonal antibody capable of analysing subpopulations of hematopoietic and lymphoid cells, and the degree of T cell differentiation. It can be used to identify the effect of CD45 in immune function. |
| Conjugation: | Unconjugated |
| Isotype: | IgG1 |
| Molecular weight: | 180-220 kDa |
| Immunogen: | Human peripheral blood mononuclear cells. |
| Immunogen Uniprot ID: | P08575 |
| Myeloma used: | P3/NS1/1-Ag4.1 |
| Target background: | Anti-PTPRC (Hle-1) monoclonal antibody binds transmembrane protein tyrosine phosphatase receptor type C (PTPRC), also known as CD45 antigen or leukocyte common antigen (LCA). Anti-PTPRC can be used in a panel of several monoclonal antibodies to characterise tumours. This antibody was created to investigate the similarities between normal thymocyte subpopulations and leukaemia's of thymic origin (Thy-ALL), and aid with leukaemia diagnosis. PTPRC is present on all leukocytes. CD45 helps regulate T cell receptor-associated kinases and Janus kinases which transmit signals from cytokine receptors. This regulates the threshold of T cell antigen receptor (TCR) signalling through dephosphorylation of protein tyrosine kinases (e.g. Lck and Fyn). It is only expressed on nucleated hemopoietic cells (~10% of cell surface). CD45 phosphatase activity is required for efficient lymphocyte antigen receptor signal transduction. CD45 is a positive and negative regulator of Src family members, and can act as a JAK phosphatase, negatively regulating cytokine receptor activation (related to differentiation, proliferation and anti-viral immunity of hemopoietic cells). |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | Store at -20° C frozen. Avoid repeated freeze / thaw cycles |
| Shipping conditions: | Dry ice |
| References: |
Di Liberto et al. 2016. Clin Transl Gastroenterol. 7(7):e178. PMID: 27388423. Lee et al. 2004. Int Immunol. 16(8):1109-24. PMID: 15210650. Tchilian et al. 2001. J Immunol. 166(2):1308-13. PMID: 11145714. Bradstock et al. 1980. J Natl Cancer Inst. 65(1):33-42. PMID: 6993744. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151022 | Anti-IL12 [1-1A4] |
Key Info
Anti-IL12 [1-1A4]
|
View Tool | |||||||||||||||||||
| 151024 | Anti-Hairy [1/24] |
Key Info
Anti-Hairy [1/24]
|
View Tool | |||||||||||||||||||
| 151027 | Anti-HSVICP8 [10A3] |
Key Info
Anti-HSVICP8 [10A3]
|
View Tool | |||||||||||||||||||
| 151033 | Anti-HSVUL42 [13C9] |
Key Info
Anti-HSVUL42 [13C9]
|
View Tool | |||||||||||||||||||
| 151034 | Anti-HSVUL42 [13D11] |
Key Info
Anti-HSVUL42 [13D11]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.